NEW YORK (GenomeWeb News) – GMSbiotech and Pure Transplant Solutions today announced a partnership to develop a new antibody screening solution.

The partnership leverages GMSbiotech's microarray-based diagnostic platform for personalized medicine and transplantation compatibility and PTS' HLA reagents, which include more than 200 Class I and II alleles. That number is anticipated to grow to more than 300 alleles during the course of the deal announced today, GMSbiotech and PTS said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.